Multisystemic, Possibly Familial Sarcoidosis Ameliorated by an mTOR Inhibitor.

Roxxy Brown, Sharon Macrohon-Sabaitue, Mark Specterman, Angeliki Asimaki

Abstract readCase Reports

In one paragraph

Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Use of Sirolimus, an mTOR Inhibitor, to Treat Sarcoidosis in Multiple Systems.Journal of cardiovascular translational research · 2025
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Roxxy BrownStrate Medical Research, North Miami, Florida, USA.

Sharon Macrohon-SabaituePrimary Medical Physicians, Zenith Clinical Research, Memorial Hospital System, Hollywood, Florida, USA.

Mark SpectermanCardiovascular and Genomics Research Institute, School of Health & Medical Sciences, City St. George's, University of London, London, United Kingdom.

Angeliki AsimakiCardiovascular and Genomics Research Institute, School of Health & Medical Sciences, City St. George's, University of London, London, United Kingdom. Electronic address: aasimaki@sgul.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSarcoidosis is an inflammatory, multisystemic, potentially life-threatening disease with a precise etiology that remains largely unknown. It is characterized by granuloma formation in various organs that can lead to permanent organ scarring and failure. Currently there is no curative treatment. Traditional drug interventions target reduction of inflammation and symptom control and have not shown definitive proof of a survival benefit. CASE SUMMARY: We present the cases of a mother and son treated for chronic aggressive multiorgan sarcoidosis with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor. Both patients experienced a marked reversal of inflammation in their respective affected organs coupled with profound symptom relief.

conclusionsInhibition of mTOR may be an effective, safe treatment option for patients with conventional-drug-resistant forms of systemic sarcoidosis.

Indexed as

autoimmuneejection fractionventricular tachycardia

Identifiers

PMID40514125

DOI10.1016/j.jaccas.2025.103633

PMCPMC12237754

What Socratic holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.